[1]Wells RG.Liver fibrosis:challenges of the new era[J].Gastroenterology, 2009, 136 (2) :387-388.
|
[2]Vinas O, Bataller R, Sancho-Bru P, et al.Human hepatic stellate cells show features of antigen-presenting cells and stimulate lymphocyte proliferation[J].Hepatology, 2003, 38 (4) :919-929.
|
[3]中华医学会.病毒性肝炎防治方案[J].中华传染病杂志, 2001, 19 (1) :56-62.
|
[4]Manning DS, Afdhal NH.Diagnosis and quantitation off ibro-sis[J].Gastroenterology, 2008, 134 (6) :1670-1681.
|
[5]Winau F, Hegasy G, Weiskirchen R, et al.II to cells are liver-resident antigen-presenting cells for activating T cell re-sponses[J].Immunity, 2007, 26 (1) :117-129.
|
[6]akaguchi S, Sakaguchi N, Asano M, et al.Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25) .Breakdown of a single mech-anism of self-tolerance causes various autoinunune disea-ses[J].J Inmunol, 1995, 155 (3) :1151-1164.
|
[7]Fontenot JD, Rudensky AY.A well adapted regulatory con-trivance:regulatory Tcell development and the forkhead fami-ly transcription factor Foxp3[J].Nat Immunol, 2005, 6 (4) :331-337.
|
[8]Seddiki N, Santner-Nanan B, Martinson J, et al.Expres-sion of interleukin (IL) -2 and IL-7 receptors discrimi-nates between human regulatory and activated T cells[J].J Exp Med, 2006, 203 (7) :1693-1700.
|
[9]Liu W, Putnam AL, Xu-Yu Z, et al.CD127 expression in-versely correlates with FoxP3 and suppressive function of hu-man CD4+ Treg cells[J].J Exp Med, 2006, 203 (7) :1701-1711.
|
[10]Belkaid Y, Piccirillo CA, Mendez S, et al.CD4+CD25+regu-latory T cel1s control Leishmania major persistence and im-munity[J].Nature, 2002, 420 (6915) :502-507.
|
[11]Boettler T, Spangenberg HC, Neumann-Haefelin C, et al.T cells witha CD4+CD25+regulatory phenotype suppress in vitro proliferation of virus-specific CD8+T cells during chro-nic hepatitis C virus infection[J].J Virol, 2005, 79 (12) :7860-7867.
|
[12]Franzese O, Kennedy PT, Gehring AJ, et al.Modulation of the CD8+-T-cell response by CD4+CD25+regulatory T cells inpatients with hepatitis B virus infection[J].J virol, 2005, 79 (6) :3322-3328.
|
[1] | Gao YuDi, Tian Yuan, Zhang XiangYing, Zhang XiaoHui, Duan ZhongPing, Ren Feng, Chen Yu. Effect of magnesium isoglycyrrhizinate on concanavalin A-induced acute liver failure in mice[J]. Journal of Clinical Hepatology, 2020, 36(7): 1571-1576. doi: 10.3969/j.issn.1001-5256.2020.07.024 |
[2] | Du XiaoFei, Chen Jie, Huang ChunYang, Zhang XiaoDan, Liu Dan, Bian XinQu, Han Ying, Liu YanMin, Dan Jing. Clinical effect and safety of magnesium isoglycyrrhizinate in treatment of autoimmune-like drug-induced liver injury[J]. Journal of Clinical Hepatology, 2020, 36(6): 1330-1333. doi: 10.3969/j.issn.1001-5256.2020.06.028 |
[3] | Expert Committee on Clinical Application of Glycyrrhizin Preparation in the Treatment of Liver Diseases. Expert consensus on clinical application of glycyrrhizin preparation in the treatment of liver diseases[J]. Journal of Clinical Hepatology, 2016, 32(5): 844-852. doi: 10.3969/j.issn.1001-5256.2016.05.004 |
[4] | Li XiaoHui, Wen Yu, Jin WenHui, Hong Zhuan, Ceng MeiYan, Chen WeiZhu. Compatible stability of magnesium isoglycyrrhizinate injection and reduced glutathione for injection[J]. Journal of Clinical Hepatology, 2016, 32(1): 143-147. doi: 10.3969/j.issn.1001-5256.2016.01.028 |
[5] | Li XiaoPeng, Li Ming, Lei Wan, Zhang LunLi. Protective effect of magnesium isoglycyrrhizinate in rats with acute liver failure induced by D- galactosamine[J]. Journal of Clinical Hepatology, 2016, 32(3): 545-548. doi: 10.3969/j.issn.1001-5256.2016.03.032 |
[6] | Mao HaiYing, Kang Tao, Yao Ling, Chen Qin. Efficacy of glycyrrhizin in patients with chronic severe hepatitis B:a meta-analysis[J]. Journal of Clinical Hepatology, 2015, 31(1): 63-67. doi: 10.3969/j.issn.1001-5256.2015.01.014 |
[7] | Ji HuiChun, Liu QingDe, Wang HongQi, Li Juan, Zhu Yun, Sun Yang, Zhou ZhongHai, Liu JunQuan. Clinical efficacy of puerarin combined with compound ammonium glycyrrhetate S in treatment of alcoholic hepatitis[J]. Journal of Clinical Hepatology, 2014, 30(10): 1067-1070. doi: 10.3969/j.issn.1001-5256.2014.10.023 |
[8] | Wang XiaoPeng, Su He, Tian HongWei, Zhang SuYu, Wu ZiYan, An YaLi, Ma YunTao. Clinical efficacy of magnesium isoglycyrrhizinate in treatment of liver injury among patients with obstructive jaundice after percutaneous transhepatic cholangiodrainage[J]. Journal of Clinical Hepatology, 2014, 30(6): 563-566. doi: 10.3969/j.issn.1001-5256.2014.06.022 |
[9] | Luo XiaoKe, Li XiaoLing, Yang LiMing, Wang XiaoHong. Efficacy of magnesium isoglycyrrhizinate in treatment of hepatitis E with severe jaundice[J]. Journal of Clinical Hepatology, 2014, 30(6): 537-539. doi: 10.3969/j.issn.1001-5256.2014.06.014 |
[10] | Xu ZhongNan, Wu XiMing, Wang Pei, Zhang XiQuan, Xia ChunGuang, Wang XunQiang, Wang Yang, Zhan XiaoLe, Qu Ying, Xu MingYi, Lu LunGen. 18α glycyrrhizic acid in the treatment of acute liver injury induced by D-galactosamine in rats[J]. Journal of Clinical Hepatology, 2012, 28(1): 63-65+70. |
[11] | Jing XiaoZhen, Liu Jing, Qian Hai. The therapeutic efficacy of magnesium isoglycyrrhizinate on rats with non alcoholic steatohepatitis[J]. Journal of Clinical Hepatology, 2011, 27(3): 295-297. |
[12] | Suo HaiFen, Zhu YaoJu. Effect of sophocarpidine and diammonium glycyrrhizinate injection on hepatic fibrosis and the content of interferon-γ of chronicity type B Hepatitis patients[J]. Journal of Clinical Hepatology, 2010, 26(2): 196-198. |
[16] | Li YunRu, Wang WenBing, Zhang LiYing, Ou YuNi, Xie Wen, Wei Lai. The analysis of efficacy of glycyrrhizin therapy for autoimmune hepatitis[J]. Journal of Clinical Hepatology, 2007, 23(2): 117-118. |
[18] | Yin HeKun, Li QiXiang, Luo Dan. The clinical study of L-ornithine-L-aspartate combined with SNMC for hepatic encephalopathy of liver cirrhosis[J]. Journal of Clinical Hepatology, 2007, 23(4): 268-269. |
[20] | Li YongXin, Gao QingWei, Wang YingLan. Analysis on clinical efficacy of Thiamine and Drammonium glycyrrhizinate concerning the treatment of chronic hepatitis B[J]. Journal of Clinical Hepatology, 2003, 19(4): 226-227. |